A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB0024 in Adult Patients With Advanced Solid Tumors (Arresto Biosciences AB0024-101).

Trial Profile

A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB0024 in Adult Patients With Advanced Solid Tumors (Arresto Biosciences AB0024-101).

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Feb 2015

At a glance

  • Drugs Simtuzumab (Primary)
  • Indications Colorectal cancer; Neuroendocrine tumours; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 02 May 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
    • 02 May 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
    • 02 May 2012 Company (Gilead Sciences) added and actual patient number is 32 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top